AbbVie’s Business Development, Cancer Plans Not Put Off By Stemcentrx Disappointments

At J.P. Morgan, AbbVie said the clinical struggles of Rova-T won’t alter its deal-making plans and leave it with plenty of solid tumor possibilities. The pharma took a $4bn write-off of the Stemcentrx deal on Jan. 4.

Business concept illustration of a businessman being guided by a hand holding a flashlight uncovering arrow sign.

AbbVie Inc.’s $5.8bn purchase of Stemcentrx Inc. in 2016 was intended to add promising solid tumor oncology candidates to its pipeline, but after multiple clinical trial disappointments with lead candidate rovalpituzumab tesirine (Rova-T), the pharma recently took a $4bn impairment charge on the deal. At the J.P. Morgan Healthcare Conference, AbbVie President Michael Severino said that result won’t affect the firm’s deal-making plans and that AbbVie still has significant solid tumor assets in-house.

The Chicago-area drug maker halted the Phase III TAHOE study of Rova-T in second-line small cell lung cancer (SCLC) in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.